Table 1.
Patient characteristics.
Table 2.
IST therapy of SAA patients.
Figure 1.
Levels of liver enzymes at diagnosis of acute hepatitis and hepatitis-associated severe aplastic anemia (HAAA).
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were at a lower level at diagnosis of HAAA than during the course of the preceding acute hepatitis. (*P<0.05, **P<0.05)
Figure 2.
Analysis of T-cell subsets in peripheral blood of patients with hepatitis-associated aplastic anemia (HAAA) and non-hepatitis-associated severe aplastic anemia (Non-HASAA).
We used a case-control study and collected random cases in non-HASAA patients as contrast group (ratio 1:4). (A) Compared with non-HASAA patients, those with HAAA had a smaller proportion of CD4+ T cells and a larger proportion of CD8+ T cells (*P<0.05, **P<0.05). (HAAA n = 36, Non-HASAA n = 144) (B) The ratio of CD4+/CD8+ T cells in HAAA patients was lower than that of non-HASAA patients (***P<0.05). (HAAA n = 36, Non-HASAA n = 144) (C) HAAA patients had a smaller proportion of CD4+CD25+ T cells than those with non-HASAA (****P<0.05). (The Data was collected since 2003, HAAA n = 28, Non-HASAA n = 112).(D) The absolute number of CD4+ T cells in HAAA patients was lower than that of non-HASAA patients (#P<0.05). (E) The absolute number of CD8+ T cells in HAAA patients was higher than that of non-HASAA patients (##P<0.05). (F) The proportion of CD4+CD25+ T cells was lower than that of non-HASAA patients (###P<0.05).
Figure 3.
Levels of proflammatory cytokines, IL-2 and TNF-α, in the serum of patients with hepatitis-associated aplastic anemia (HAAA) and non-hepatitis-associated severe aplastic anemia (Non-HASAA).
We used a case-control study and collected random cases in non-HASAA patients as contrast group (ratio 1:4). Patients with HAAA had (A) a higher serum IL-2 level (*P<0.05) and (B) a higher serum TNF-α level (**P<0.05) than non-HASAA patients. (HAAA n = 36, Non-HASAA n = 144)
Figure 4.
Comparison of early infection rates and infection-related mortality in patients with hepatitis-associated aplastic anemia (HAAA) and non-hepatitis-associated severe aplastic anemia (Non-HASAA).
(A) HAAA patients had a higher early infection rate than non-HASAA patients (*P<0.05) and (B) higher infection-related mortality than non-HASAA patients among 2 years (**P<0.05).
Figure 5.
Kaplan-Meier curve showing overall survival of HAAA patients (n = 36).
The 2-year survival rate of the HAAA group was 16.6%.